Macrophage Activation Syndrome
2
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Swedish Orphan BiovitrumMA - Waltham
3 programs1
1
EmapalumabPhase 3Monoclonal Antibody1 trial
EmapalumabPhase 2Monoclonal Antibody1 trial
Chart reviewN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Swedish Orphan BiovitrumEmapalumab
Swedish Orphan BiovitrumEmapalumab
Swedish Orphan BiovitrumChart review
Clinical Trials (3)
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Start: Dec 2021Est. completion: Jun 2025
Phase 3Completed
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Start: Feb 2018Est. completion: May 2020
Phase 2Completed
Assessment of Macrophage Activation syndromE in STill's Disease
Start: Sep 2023Est. completion: Sep 2024
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Monoclonal Antibody is the dominant modality (100% of programs)
1 companies competing in this space